Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer

Tang, Zhaoqing; Gu, Yuan; Shi, Zhongyi; Min, Lingqiang; Zhang, Ziwei; Zhou, Pingzhu; Luo, Rongkui; Wang, Yan; Cui, Yuehong; Sun, Yihong; Wang, Xuefei

doi:10.1016/j.xcrm.2023.100931

Cited by 9 publications

(6 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serological markers offer significant benefits for tumor diagnosis and monitoring, such as non-invasiveness and reproducibility. Tumor detection via serum proteomics provides a sensitive and informative alternative to tissue samples due to its systemic perspective [ 35 ]. Alpha-fetoprotein (AFP) is a specific serum glycoprotein vital for liver cancer diagnosis; however, its sensitivity and specificity are limited.…”

Section: Discussionmentioning

confidence: 99%

PPIH acts as a potential predictive biomarker for patients with common solid tumors

Ye,

Ying,

Chen

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Our previous studies have indicated that mRNA and protein levels of PPIH are significantly upregulated in Hepatocellular Carcinoma (LIHC) and could act as predictive biomarkers for patients with LIHC. Nonetheless, the expression and implications of PPIH in the etiology and progression of common solid tumors have yet to be explored, including its potential as a serum tumor marker. Methods We employed bioinformatics analyses, augmented with clinical sample evaluations, to investigate the mRNA and protein expression and gene regulation networks of PPIH in various solid tumors. We also assessed the association between PPIH expression and overall survival (OS) in cancer patients using Kaplan-Meier analysis with TCGA database information. Furthermore, we evaluated the feasibility and diagnostic efficacy of PPIH as a serum marker by integrating serological studies with established clinical tumor markers. Results Through pan-cancer analysis, we found that the expression levels of PPIH mRNA in multiple tumors were significantly different from those in normal tissues. This study is the first to report that PPIH mRNA and protein levels are markedly elevated in LIHC, Colon adenocarcinoma (COAD), and Breast cancer (BC), and are associated with a worse prognosis in these cancer patients. Conversely, serum PPIH levels are decreased in patients with these tumors (LIHC, COAD, BC, gastric cancer), and when combined with traditional tumor markers, offer enhanced sensitivity and specificity for diagnosis. Conclusion Our findings propose that PPIH may serve as a valuable predictive biomarker in tumor patients, and its secreted protein could be a potential serum marker, providing insights into the role of PPIH in cancer development and progression.

show abstract

Section: Discussionmentioning

confidence: 99%

PPIH acts as a potential predictive biomarker for patients with common solid tumors

Ye,

Ying,

Chen

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Aiming to mine the correlation between clinical indicators and pathological stages, we performed weighted gene coexpression network analysis (WGCNA) (STAR Methods), which is an unsupervised method to identify groups of coregulated proteins and their association with clinical variables 22 . (Fig.…”

Section: The Clta-psmd6-neutrophil Axis Promotes Breast Cancer Metast...mentioning

confidence: 99%

“…Compared with traditional detection methods for tumor diagnosis, liquid biopsy possesses many advantages; it is less invasive and easier to perform and has fewer complications and stronger dynamic monitoring ability, and a higher acceptance rate 18 . Serum, a bodily uid, could represent an essential component of the liquid biopsy test 22 .…”

Section: Introductionmentioning

confidence: 99%

Proteome profiling of serum reveals PSMD6 as a biomarker in breast cancer metastasis

Ding,

Meng,

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Breast cancer (BC) has the highest mortality rate and prevalence among cancers in females worldwide. Here, we performed proteomic profiling of 322 serum samples from the discovery cohort [56 healthy controls (HCs), 112 benign breast tumor (BBT) patients, and 154 BC patients] and a prospective validation cohort [27 HCs, 29 BBT patients and 57 BC patients]. Integrated proteomic analysis of tissue and serum samples revealed highly specific tumor biomarkers and demonstrated that the serum proteome can distinguish the different pathological substages in BC progression. We also identified PSMD6 as a potential metastatic breast cancer (MBC) biomarker. Comprehensive analysis of the multicenter independent validation cohort, which included retrospective and prospective cohorts including 61 HCs, 72 BBT patients, and 247 BC patients, indicated that PSMD6 overexpression was an important cause of BC metastasis and an indicator of poor prognosis. Further study revealed that the CLTA-PSMD6-neutrophil axis promotes the transition from invasive ductal carcinoma (IDC) to MBC. Importantly, CLTA amplification might be a potential therapeutic target for MBC patients. We also developed a highly accurate predictive model (accuracy = 0.87) to differentiate benign and malignant tumors and validated its good performance in the prospective validation cohort. Collectively, this study demonstrates the elaborate BC serum proteomic landscape and provides valuable information regarding serum biomarkers, which could reveal novel therapeutic targets and provide opportunities for MBC treatment.

show abstract

“…To our knowledge, Olink ® technology has not been used yet in the context of GJ. However, different reports point out the utility of using serum as a biological sample in predicting responses to preoperative chemotherapy for GC [72] and characterizing novel immunological GC biomarkers [73][74][75][76].…”

Section: Deployment Of Proteomics In Gastric Juicementioning

confidence: 99%

The Human Gastric Juice: A Promising Source for Gastric Cancer Biomarkers

Felípez,

Montori,

Mendizuri

et al. 2023

IJMS

View full text Add to dashboard Cite

Gastric cancer (GC) is a major public health problem worldwide, with high mortality rates due to late diagnosis and limited treatment options. Biomarker research is essential to improve the early detection of GC. Technological advances and research methodologies have improved diagnostic tools, identifying several potential biomarkers for GC, including microRNA, DNA methylation markers, and protein-based biomarkers. Although most studies have focused on identifying biomarkers in biofluids, the low specificity of these markers has limited their use in clinical practice. This is because many cancers share similar alterations and biomarkers, so obtaining them from the site of disease origin could yield more specific results. As a result, recent research efforts have shifted towards exploring gastric juice (GJ) as an alternative source for biomarker identification. Since GJ is a waste product during a gastroscopic examination, it could provide a “liquid biopsy” enriched with disease-specific biomarkers generated directly at the damaged site. Furthermore, as it contains secretions from the stomach lining, it could reflect changes associated with the developmental stage of GC. This narrative review describes some potential biomarkers for gastric cancer screening identified in gastric juice.

show abstract

Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer

Cited by 9 publications

References 63 publications

PPIH acts as a potential predictive biomarker for patients with common solid tumors

PPIH acts as a potential predictive biomarker for patients with common solid tumors

Proteome profiling of serum reveals PSMD6 as a biomarker in breast cancer metastasis

The Human Gastric Juice: A Promising Source for Gastric Cancer Biomarkers

Contact Info

Product

Resources

About